|
1
|
Aísa-Marín I, López-Iniesta MJ, Milla S,
Lillo J, Navarro G, de la Villa P and Marfany G: Nr2e3 functional
domain ablation by CRISPR-Cas9D10A identifies a new isoform and
generates retinitis pigmentosa and enhanced S-cone syndrome models.
Neurobiol Dis. 146(105122)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Li S, Datta S, Brabbit E, Love Z,
Woytowicz V, Flattery K, Capri J, Yao K, Wu S, Imboden M, et al:
Nr2e3 is a genetic modifier that rescues retinal degeneration and
promotes homeostasis in multiple models of retinitis pigmentosa.
Gene Ther. 28:223–241. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Khanal T, Leung YK, Jiang W, Timchenko N,
Ho SM and Kim K: NR2E3 is a key component in p53 activation by
regulating a long noncoding RNA DINO in acute liver injuries. FASEB
J. 33:8335–8348. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Garattini E, Bolis M, Paroni G, Fratelli M
and Terao M: Lipid-sensors, enigmatic-orphan and orphan nuclear
receptors as therapeutic targets in breast-cancer. Oncotarget.
7:42661–42682. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Park YY, Kim K, Kim SB, Hennessy BT, Kim
SM, Park ES, Lim JY, Li J, Lu YL, Gonzalez-Angulo AM, et al:
Reconstruction of nuclear receptor network reveals that NR2E3 is a
novel upstream regulator of ESR1 in breast cancer. EMBO Mol Med.
4:52–67. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhao Z, Wang L and Xu W: IL-13Rα2 mediates
PNR-induced migration and metastasis in ERα-negative breast cancer.
Oncogene. 34:1596–1607. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bracci PM, Zhou M, Young S and Wiemels J:
Serum autoantibodies to pancreatic cancer antigens as biomarkers of
pancreatic cancer in a San Francisco Bay Area case-control study.
Cancer. 118:5384–5394. 2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Eichen JG, Dalmau J, Demopoulos A, Wade D,
Posner JB and Rosenfeld M: The photoreceptor cell-specific nuclear
receptor is an autoantigen of paraneoplastic retinopathy. J
Neuroophthalmol. 21:168–172. 2001.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Khanal T, Choi K, Leung YK, Wang J, Kim D,
Janakiram V, Cho SG, Puga A, Ho SM and Kim K: Loss of NR2E3
represses AHR by LSD1 reprogramming, is associated with poor
prognosis in liver cancer. Sci Rep. 7(10662)2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhang L, Chen W, Liu S and Chen C:
Targeting breast cancer stem cells. Int J Biol Sci. 19:552–570.
2023.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Taurin S and Alkhalifa H: Breast cancers,
mammary stem cells, and cancer stem cells, characteristics, and
hypotheses. Neoplasia. 22:663–678. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lim JR, Mouawad J, Gorton OK, Bubb WA and
Kwan AH: Cancer stem cell characteristics and their potential as
therapeutic targets. Med Oncol. 38(76)2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Rahmati M, Johari B, Kadivar M, Rismani E
and Mortazavi Y: Suppressing the metastatic properties of the
breast cancer cells using STAT3 decoy oligodeoxynucleotides: A
promising approach for eradication of cancer cells by
differentiation therapy. J Cell Physiol. 235:5429–5444.
2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Johari B, Rahmati M, Nasehi L, Mortazavi
Y, Faghfoori MH and Rezaeejam H: Evaluation of STAT3 decoy
oligodeoxynucleotides' synergistic effects on radiation and/or
chemotherapy in metastatic breast cancer cell line. Cell Biol Int.
44:2499–2511. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Johari B and Moradi M: Application of
transcription factor decoy oligodeoxynucleotides (ODNs) for cancer
therapy. Methods Mol Biol. 2521:207–230. 2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bai X, Ni J, Beretov J, Graham P and Li Y:
Cancer stem cell in breast cancer therapeutic resistance. Cancer
Treat Rev. 69:152–163. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Muscat GEO, Eriksson NA, Byth K, Loi S,
Graham D, Jindal S, Davis MJ, Clyne C, Funder JW, Simpson ER, et
al: Research resource: Nuclear receptors as transcriptome:
discriminant and prognostic value in breast cancer. Mol Endocrinol.
27:350–365. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Xie S, Han S, Qu Z, Liu F, Li J, Yu S,
Reilly J, Tu J, Liu X, Lu Z, et al: Knockout of Nr2e3 prevents rod
photoreceptor differentiation and leads to selective L-/M-cone
photoreceptor degeneration in zebrafish. Biochim Biophys Acta Mol
Basis Dis. 1865:1273–1283. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wang W, Zhang L, Wang Y, Ding Y, Chen T,
Wang Y, Wang H, Li Y, Duan K, Chen S, et al: Involvement of miR-451
in resistance to paclitaxel by regulating YWHAZ in breast cancer.
Cell Death Dis. 8(e3071)2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yan Y, Liu F, Han L, Zhao L, Chen J,
Olopade OL, He M and Wei M: HIF-2α promotes conversion to a stem
cell phenotype and induces chemoresistance in breast cancer cells
by activating Wnt and Notch pathways. J Exp Clin Cancer Res.
37(256)2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Gooding AJ and Schiemann WP:
Epithelial-mesenchymal transition programs and cancer stem cell
phenotypes: Mediators of breast cancer therapy resistance. Mol
Cancer Res. 18:1257–1270. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Recouvreux MV, Moldenhauer MR, Galenkamp
KMO, Jung M, James B, Zhang Y, Lowy A, Bagchi A and Commisso C:
Glutamine depletion regulates Slug to promote EMT and metastasis in
pancreatic cancer. J Exp Med. 217(e20200388)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Venturini G, Kokona D, Steiner BL, Bulla
EG, Jovanovic J, Zinkernagel MS and Escher P: In vivo analysis of
onset and progression of retinal degeneration in the Nr2e3rd7/rd7
mouse model of enhanced S-cone sensitivity syndrome. Sci Rep.
11(19032)2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Choi MY, Romer AI, Hu M, Lepourcelet M,
Mechoor A, Yesilaltay A, Krieger M, Gray PA and Shivdasaniet RA: A
dynamic expression survey identifies transcription factors relevant
in mouse digestive tract development. Development. 133:4119–4129.
2006.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Nishimura M, Naito S and Yokoi T:
Tissue-specific mRNA expression profiles of human nuclear receptor
subfamilies. Drug Metab Pharmacokinet. 19:135–149. 2004.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Cai X, Conley SM, Cheng T, Al-Ubaidi MR
and Naash MI: A 350 bp region of the proximal promoter of Rds
drives cell-type specific gene expression. Exp Eye Res. 91:186–194.
2010.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wen Z, Pyeon D, Wang Y, Lambert P, Xu W
and Ahlquist P: Orphan nuclear receptor PNR/NR2E3 stimulates p53
functions by enhancing p53 acetylation. Mol Cell Biol. 32:26–35.
2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Garancher A, Lin CY, Morabito M, Richer W,
Rocques N, Larcher M, Bihannic L, Smith K, Miquel C, Leboucher S,
et al: NRL and CRX define photoreceptor identity and reveal
subgroup-specific dependencies in medulloblastoma. Cancer Cell.
33:435–449.e6. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Al-Khuzaei S, Broadgate S, Halford S,
Jolly JK, Shanks M, Clouston P and Downes SM: Novel pathogenic
sequence variants in NR2E3 and clinical findings in three patients.
Genes (Basel). 11(1288)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Khanal T, Kim D, Johnson A, Choubey D and
Kim K: Deregulation of NR2E3, an orphan nuclear receptor, by
benzo(a)pyrene-induced oxidative stress is associated with histone
modification status change of the estrogen receptor gene promoter.
Toxicol Lett. 237:228–236. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Lin SJ, Yang DR, Yang G, Lin CY, Chang HC,
Li G and Chang C: TR2 and TR4 orphan nuclear receptors: An
overview. Curr Top Dev Biol. 125:357–373. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Haider NB, Mollema N, Gaule M, Yuan Y,
Sachs AJ, Nystuen AM, Naggert JK and Nishina PM: Nr2e3-directed
transcriptional regulation of genes involved in photoreceptor
development and cell-type specific phototransduction. Exp Eye Res.
89:365–372. 2009.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Roduit R, Escher P and Schorderet DF:
Mutations in the DNA-binding domain of NR2E3 affect in vivo
dimerization and interaction with CRX. PLoS One.
4(e7379)2009.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Yao X, Zhang Y, Wu L, Cheng R, Li C, Qu C
and Ji H: Immunohistochemical study of NR2C2, BTG2, TBX19, and CDK2
expression in 31 paired primary/recurrent nonfunctioning pituitary
adenomas. Int J Endocrinol. 2019(5731639)2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zhang L, Zhang J, Ma Y, Chen J, Dong B,
Zhao W, Wang X, Zheng Q, Fang F and Yang Y: Testicular orphan
receptor 4 (TR4) is a marker for metastasis and poor prognosis in
non-small cell lung cancer that drives the EMT phenotype. Lung
Cancer. 89:320–328. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Qiu X, Zhu J, Sun Y, Fan K, Yang DR, Li G,
Yang G and Chang C: TR4 nuclear receptor increases prostate cancer
invasion via decreasing the miR-373-3p expression to alter
TGFβR2/p-Smad3 signals. Oncotarget. 6:15397–15409. 2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Fan Z, Zheng J, Xue Y, Liu X, Wang D, Yang
C, Ma J, Liu L, Ruan X, Wang Z and Liu Y: NR2C2-uORF targeting
UCA1-miR-627-5p-NR2C2 feedback loop to regulate the malignant
behaviors of glioma cells. Cell Death Dis. 9(1165)2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ren W, Hu J, Li H, Chen J, Ding J, Zu X
and Fan B: miR-616-5p promotes invasion and migration of bladder
cancer via downregulating NR2C2 expression. Front Oncol.
11(762946)2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Jin R, Lin H, Li G, Xu J, Shi L, Chang C
and Cai X: TR4 nuclear receptor suppresses HCC cell invasion via
downregulating the EphA2 expression. Cell Death Dis.
9(283)2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Shyr CR, Hu YC, Kim E and Chang C:
Modulation of estrogen receptor-mediated transactivation by orphan
receptor TR4 in MCF-7 cells. J Biol Chem. 277:14622–14628.
2002.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Gervin E, Shin B, Opperman R, Cullen M,
Feser R, Maiti S and Majumder M: Chemically induced hypoxia
enhances miRNA functions in breast cancer. Cancers (Basel).
12(2008)2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Yang SF, Hou MF, Chen FM, Ou-Yang F, Wu
YC, Chai CY and Yeh YT: Prognostic value of protein inhibitor of
activated STAT3 in breast cancer patients receiving hormone
therapy. BMC Cancer. 16(20)2016.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Lei JT, Gou X, Seker S and Ellis MJ: ESR1
alterations and metastasis in estrogen receptor positive breast
cancer. J Cancer Metastasis Treat. 5(38)2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Matutino A, Joy AA, Brezden-Masley C, Chia
S and Verma S: Hormone receptor-positive, HER2-negative metastatic
breast cancer: Redrawing the lines. Curr Oncol. 25 (Suppl
1):S131–S141. 2018.PubMed/NCBI View Article : Google Scholar
|
